Newshot 
The Cas9 protein together with RNA and DNA (orange; artist’s illustration). A new therapy uses the CRISPR-Cas9 gene editing system to treat a rare genetic disease called hereditary angioedema.Credit: Alfred Pasieka/Science Photo Library
A pioneering therapy that edits genes inside a recipient’s body continues to be effective four years after treatment, according to data released by its developer, Intellia Therapeutics.
The therapy, named lonvoguran ziclumeran (lonvo-z), was designed to treat one form of a genetic disorder that causes episodes of painful and potentially dangerous swelling in the throat and other parts of the body. Lonvo-z deploys the CRISPR-Cas9 gene-editing system to disable the gene that produces prekallikrein, a protein made in the liver that promotes blood-vessel leakage.
Bigger than CRISPR? A guide to the latest genome editors
Intellia, headquartered in Cambridge, Massachusetts, has applied for approval of lonvo-z to the US Food and Drug Administration (FDA), which is expected to issue a decision by 10 March. If approved, the therapy will become the world’s first CRISPR medicine to be delivered directly inside the body, or in vivo, John Leonard, Intellia’s chief executive, told investors on 12 November. Currently, the only CRISPR therapy approved by the FDA is performed on cells that have first been removed from the body and are subsequently re-infused.
For people with the condition, hereditary angioedema, the gene-editing approach could offer relief from a lifetime of juggling medications to prevent and treat swelling attacks, says Jonathan Bernstein, a hereditary angioedema specialist at the University of Cincinnati in Ohio and an investigator on a lonvo-z trial. “It’s very reassuring,” he says of the four-year data. “That’s what you’re supposed to see.”
Inside job
The only approved CRISPR therapy is Casgevy, a treatment for two genetic blood disorders, sickle cell anemia and ß-thalassemia. To create a dose of Casgevy, physicians first remove blood stem cells from the recipient, then send them off for gene editing. The edited cells are infused back into the recipient.
The therapy must be made anew for each person, adding time, cost, and complexity. The recipient also has to undergo harsh chemotherapy treatment to make room for the edited cells.
CRISPR makes enhanced cancer-fighting immune cells inside mice
In vivo gene-editing approaches aim to sidestep these concerns by editing genes directly in the body. Lonvo-z, for example, consists of fatty particles that encase mRNA encoding CRISPR-Cas9 components. The particles are infused into the blood and taken up by the liver, where prekallikrein is produced. The procedure takes one day.
In vivo gene editing can introduce other safety concerns, however. The therapy affords no opportunity to screen out cells with unwanted edits at other locations in the genome, or in other organs. Recipients might also have harmful immune responses to the treatment.
Last year, the FDA placed a clinical hold on two other in vivo studies sponsored by Intellia after a participant — an older man with other health conditions — developed liver damage and died after receiving a CRISPR treatment. The FDA lifted the hold this year after requiring added safety measures.
Enjoying our latest content? Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
doi: https://doi.org/10.1038/d41586-026-03705-9
References
- Cohn, D. M. et al. New Engl. J. Med. 395, 1471-1482 (2026). Google Scholar
Cohn, D. M. et al. New Engl. J. Med. 395, 1471-1482 (2026).
Google Scholar
Download references
Reprints and permissions
Related Articles
- A first for CRISPR: powerful prime editing alters DNA directly in the human body
- Cancer-fighting immune cells could soon be engineered inside our bodies
- World first: ultra-powerful CRISPR treatment trialled in a person
Subjects
- CRISPR-Cas9 genome editing
- Medical research
Latest on:
- Medical research
- Record-breaking Ebola outbreak: phone data reconstruct first weeks of spread News 12 NOV 26
Record-breaking Ebola outbreak: phone data reconstruct first weeks of spread
News 12 NOV 26
- Massive atlas of brain region linked to a host of diseases is the most detailed yet News 12 NOV 26
Massive atlas of brain region linked to a host of diseases is the most detailed yet
News 12 NOV 26
- Give biologists the space to be curious, not just better tools World View 11 NOV 26
Give biologists the space to be curious, not just better tools
World View 11 NOV 26
- RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus News 12 NOV 26
RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus
News 12 NOV 26
- Move over BMI: new obesity definition is better for predicting your health News 11 NOV 26
Move over BMI: new obesity definition is better for predicting your health
News 11 NOV 26
- Parkinson’s: beyond the brain Outlook 04 NOV 26
Parkinson’s: beyond the brain
Outlook 04 NOV 26
Jobs
- Assistant Professor, Tenure Track, CHOP Division of Hematology Perelman School of Medicine at the University of Pennsylvania seek candidates for an Assistant Professor position in the tenure track. Philadelphia, Pennsylvania (US) University of Pennsylvania
Assistant Professor, Tenure Track, CHOP Division of Hematology
Perelman School of Medicine at the University of Pennsylvania seek candidates for an Assistant Professor position in the tenure track.
Philadelphia, Pennsylvania (US)
University of Pennsylvania
- Bioinformatician – Long-Read Genomics, Pangenomics and Precision Medicine Talented bioinformatician with expertise in the analysis of long-read genomic and multi-omics sequencing data, genome assembly, and pangenomics. Doha (QA) Sidra Medicine Qatar
Bioinformatician – Long-Read Genomics, Pangenomics and Precision Medicine
Talented bioinformatician with expertise in the analysis of long-read genomic and multi-omics sequencing data, genome assembly, and pangenomics.
Sidra Medicine Qatar
- Associate or Senior Editor, Communications AI & Computing Job Title: Associate or Senior Editor, Communications AI & Computing Locations: Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid) Appli... Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid) Springer Nature Ltd
Associate or Senior Editor, Communications AI & Computing
Job Title: Associate or Senior Editor, Communications AI & Computing Locations: Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid) Appli...
Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid)
Springer Nature Ltd
- Postdoctoral Fellow Postdoctoral Fellow focus on ferroic smart materials: shape-memory alloys, piezoelectric ceramics, and magnetostrictive materials, etc Ningbo, Zhejiang (CN) Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)
Postdoctoral Fellow
Postdoctoral Fellow focus on ferroic smart materials: shape-memory alloys, piezoelectric ceramics, and magnetostrictive materials, etc
Ningbo, Zhejiang (CN)
Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)
- Principal Investigator/ Associate Professor PI & Associate Professor class focus on innovative research about ferroic smart materials or technology transfer Ningbo, Zhejiang (CN) Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)
Principal Investigator/ Associate Professor
PI & Associate Professor class focus on innovative research about ferroic smart materials or technology transfer
Ningbo, Zhejiang (CN)
Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)